

# Second quarter 2017 results

Biotec Pharmacon ASA ("Biotec", OSE: BIOTEC) reported sales of NOK 16.4 million (15.3) in the second quarter of 2017, and a negative EBITDA of NOK 4.4 million (-1.6). Woulgan® generated sales of NOK 0.9, up from NOK 0.4 million in the first quarter of 2017.

ArcticZymes continued its positive sales growth and reported NOK 8.4 million in sales, an 8 percent increase from the second quarter of 2016.